We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current DRUG market cap is 158.93M. The company's latest EPS is AUD 0.9327 and P/E is 8.39.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 3.92M | 15.62M | 2.46M | 7.94M | 19.88M |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | 3.66M | 15.13M | 1.57M | 6.99M | 18.93M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 49.56M | 115.11M | 165.11M | 161.45M | 177.87M |
| Total Liabilities | 1.52M | 7.35M | 6.3M | 3.22M | 4.63M |
| Total Equity | 48.04M | 107.76M | 158.81M | 158.23M | 173.24M |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -12.34M | -50.55M | -44.16M | 7.28M | -420k |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 12.34M | 50.67M | 44.38M | -7.57M | 606k |
| Market Cap | 158.93M |
| Price to Earnings Ratio | 8.39 |
| Price to Sales Ratio | 7.99 |
| Price to Cash Ratio | 522 |
| Price to Book Ratio | 0.92 |
| Dividend Yield | - |
| Shares Outstanding | 20.3M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.18 (2.25%) |
| Company Name | BetaShares Capital Limited |
| Address |
level 11 sydney, new south wales 2000 |
| Website | https://www.betashares.com.au |
| Industry | finance services (6199) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
